The Goals of Treatment in AML

Blinatumomab integration led to high complete response and minimal residual disease-negativity rates, especially in patients over 40 and Philadelphia chromosome-positive cases.

The FDA has greenlighted blinatumomab for the treatment of patients with CD19-positive, B-cell precursor acute lymphoblastic leukemia following a priority review designation.

The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.

SH-201 is a new, promising option for certain types of leukemias, including chronic myeloid leukemia and acute lymphoblastic leukemia, as well as other cancers.

Revumenib shows promise in treating both adults and children with specific types of leukemia, with similar safety and effectiveness.

Adam de Smith, PhD, discussed findings from a study investigating a genetic variant that increases the risk of acute lymphoblastic leukemia in Hispanic/Latino pediatric patients.